Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in México

NMOSD is an inflammatory disorder of the central nervous system that primarily affects the optic nerves and spinal cord. Rituximab (RTX) is a monoclonal antibody directed against CD20, an epitope expressed on pre-B and mature B cells. It has of wide use in several antibody-mediated autoimmune diseas...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the neurological sciences 2020-12, Vol.419, p.117204-117204, Article 117204
Main Authors: Casallas-Vanegas, Adriana, Gomez-Figueroa, Enrique, de Saráchaga, Adib Jorge, Zabala-Angeles, Indhira, García-Estrada, Christian, Salado-Burbano, Jorge C., DiazGranados-Palacio, María Clara, Corona-Vázquez, Teresita, de Jesús Flores-Rivera, José, Rivas-Alonso, Verónica
Format: Article
Language:English
Subjects:
Antigen-antibody complex
Central nervous system diseases
Demyelinating autoimmune diseases
Female
Humans
Immunologic Factors - therapeutic use
Immunosuppression
Male
Mexico
Neuromyelitis Optica - drug therapy
Neuromyelitis optica spectrum disorders
Retrospective Studies
Rituximab
Rituximab - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:NMOSD is an inflammatory disorder of the central nervous system that primarily affects the optic nerves and spinal cord. Rituximab (RTX) is a monoclonal antibody directed against CD20, an epitope expressed on pre-B and mature B cells. It has of wide use in several antibody-mediated autoimmune diseases. To demonstrate RTX clinical efficacy at different initial and maintenance doses administered in patients with NMOSD. In this retrospective/observational study we recruited subjects with NMOSD with at least one RTX infusion. Annual relapse rates (ARR) were compared in several induction and maintenance regimens with RTX in 66 patients with NMOSD. Fifty-four (81.8%) were female and two thirds (66.7%) had positive anti-AQP4 antibodies. The most prevalent induction and maintenance regimens were 1000 mg on days 1 and 15 (51.5%) and 1000 mg every 6 months (40.9%), respectively. Overall, the annual relapse rate (ARR) decreased from 1.15 to 0.46 with RTX (p 
ISSN:0022-510X
1878-5883
DOI:10.1016/j.jns.2020.117204